Clinical Outcome Of Patients Treated With IMRT For Locally Advanced Anal Canal Cancer

2011 ◽  
Vol 81 (2) ◽  
pp. S377
Author(s):  
D. Azria ◽  
S. Vieillot ◽  
C. Lemanski ◽  
N. Ailleres ◽  
P. Fenoglietto
Keyword(s):  
Clinical Outcome ◽  
Anal Canal ◽  
Locally Advanced ◽  
Anal Canal Cancer

scholarly journals Carcinoma of the anal canal

2011 ◽  
Vol 3 (1) ◽  
pp. 27
Author(s):  
David T. Marshall ◽  
Charles R. Thomas Jr
Keyword(s):  
Anal Canal ◽  
Locally Advanced ◽  
The United States ◽  
Sphincter Preservation ◽  
Tumor Control ◽  
Anal Canal Cancer ◽  
Permanent Colostomy ◽  
Anti Cancer ◽  
Treatment Paradigm ◽  
Technological Developments

There are around 5,000 new cases of anal canal cancer each year in the United States. It is of particular risk in HIV-positive populations. Many cases are related to persistent infection with human papillomavirus (HPV). The treatment of anal cancer has progressed from abdominoperineal resection mandating permanent colostomy in the 1940s through the 1970s to modern chemoradiation with sphincter preservation in around 80% of patients, even with locally advanced disease. The evolution of the treatment paradigm of this disease is a model for the treatment of malignant disease with organ preservation. Multiple randomized trials have been conducted to guide this evolution. Technological developments in the delivery of radiotherapy and anti-cancer pharmaceuticals harbor hope for further improvements in outcomes with possible reductions in toxicity and increases in tumor control. Perhaps most inspiring is the recent development of HPV vaccines that

scholarly journals A Definitive IMRT-SIB with Concomitant Chemotherapy for Synchronous Locally Advanced Anal Canal Cancer and Prostate Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Tubin Slavisa ◽  
Raunik Wolfgang
Keyword(s):  
Prostate Cancer ◽  
Anal Canal ◽  
Primary Tumour ◽  
Locally Advanced ◽  
Point Of View ◽  
Anal Canal Cancer ◽  
Concomitant Chemotherapy ◽  
Anal Canal Carcinoma ◽  
Genitourinary Toxicity ◽  
Patient Reported

Currently, there are no specific recommendations regarding the management of the synchronous tumours due to the lack of either specific guidelines or individuals’ clinical experiences relative to these clinical situations. In the presence of a locally advanced double primary tumour and with the lymph node metastases in addition, from the radiotherapeutical point of view, it must be challenging to manage this complicated situation that requires a more delicate treatment planning, due to higher doses prescribed to greater volumes concomitantly with the chemotherapy. A 68-year-old Caucasian male with a synchronous intermediate-risk prostate adenocarcinoma and locally advanced anal canal carcinoma underwent IMRT-SIB with concomitant chemotherapy at our institute. Two years after the treatment, the restaging CT and MRI scan showed no evidence of the disease and the patient reported no significant gastrointestinal or genitourinary toxicity. Our experience is unique, since it is the first report on using the IMRT-SIB technique simultaneously with chemotherapy in the management of the synchronous prostate and anal canal carcinomas. Therefore, we find it important to provide the current literature with the results from our experience which show good feasibility, efficacy, and tolerability of the definitive concomitant IMRT-SIB-chemotherapy for the synchronous anal canal cancer and prostate cancer.

Concurrent Chemotherapy and Intensity-Modulated Radiation Therapy for Anal Canal Cancer Patients: A Multicenter Experience

2007 ◽  
Vol 25 (29) ◽  
pp. 4581-4586 ◽  
Author(s):  
Joseph K. Salama ◽  
Loren K. Mell ◽  
David A. Schomas ◽  
Robert C. Miller ◽  
Kiran Devisetty ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Anal Canal ◽  
Cancer Patients ◽  
Intensity Modulated Radiation Therapy ◽  
Complete Response ◽  
Concurrent Chemotherapy ◽  
Hiv Positive ◽  
Anal Canal Cancer ◽  
Intensity Modulated ◽  
Dermatologic Toxicity

PurposeTo report a multicenter experience treating anal canal cancer patients with concurrent chemotherapy and intensity-modulated radiation therapy (IMRT).Patients and MethodsFrom October 2000 to June 2006, 53 patients were treated with concurrent chemotherapy and IMRT for anal squamous cell carcinoma at three tertiary-care academic medical centers. Sixty-two percent were T1-2, and 67% were N0; eight patients were HIV positive. Forty-eight patients received fluorouracil (FU)/mitomycin, one received FU/cisplatin, and four received FU alone. All patients underwent computed tomography–based treatment planning with pelvic regions and inguinal nodes receiving a median of 45 Gy. Primary sites and involved nodes were boosted to a median dose of 51.5 Gy. All acute toxicity was scored according to the Common Terminology Criteria for Adverse Events, version 3.0. All late toxicity was scored using Radiation Therapy Oncology Group criteria.ResultsMedian follow-up was 14.5 months (range, 5.2 to 102.8 months). Acute grade 3+ toxicity included 15.1% GI and 37.7% dermatologic toxicity; all acute grade 4 toxicities were hematologic; and acute grade 4 leukopenia and neutropenia occurred in 30.2% and 34.0% of patients, respectively. Treatment breaks occurred in 41.5% of patients, lasting a median of 4 days. Forty-nine patients (92.5%) had a complete response, one patient had a partial response, and three had stable disease. All HIV-positive patients achieved a complete response. Eighteen-month colostomy-free survival, overall survival, freedom from local failure, and freedom from distant failure were 83.7%, 93.4%, 83.9%, and 92.9%, respectively.ConclusionPreliminary outcomes suggest that concurrent chemotherapy and IMRT for anal canal cancers is effective and tolerated favorably compared with historical standards.

scholarly journals Is elective inguinal radiotherapy necessary for locally advanced rectal adenocarcinoma invading anal canal?

2014 ◽  
Vol 9 (1) ◽  
Author(s):  
Seung-Gu Yeo ◽  
Hyeon Woo Lim ◽  
Dae Yong Kim ◽  
Tae Hyun Kim ◽  
Sun Young Kim ◽  
...  
Keyword(s):  
Anal Canal ◽  
Locally Advanced ◽  
Rectal Adenocarcinoma

Induction Chemotherapy in Patients With Anal Canal Cancer: A Pilot Study

2020 ◽  
Vol 19 (3) ◽  
pp. e137-e139
Author(s):  
Francesca De Felice ◽  
Daniela Musio ◽  
Vincenzo Tombolini
Keyword(s):  
Pilot Study ◽  
Anal Canal ◽  
Induction Chemotherapy ◽  
Anal Canal Cancer
Sign in / Sign up

Export Citation Format

Share Document